

# Ron J Keizer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3573750/publications.pdf>

Version: 2024-02-01

36  
papers

1,882  
citations

471371

17  
h-index

345118

36  
g-index

36  
all docs

36  
docs citations

36  
times ranked

3335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 191-203.	1.6	7
2	Continuous Learning in Model-Informed Precision Dosing: A Case Study in Pediatric Dosing of Vancomycin. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 233-242.	2.3	22
3	Use of Age-Adjusted Serum Creatinine in a Vancomycin Pharmacokinetic Model Decreases Predictive Performance in Elderly Patients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 139-140.	1.0	4
4	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1201-1215.	1.6	5
5	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4262-4272.	1.1	8
6	A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1150-1160.	1.3	20
7	Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis. <i>PLoS Computational Biology</i> , 2020, 16, e1008107.	1.5	21
8	Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2497-2506.	1.1	25
9	Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children's Hospital. <i>Frontiers in Pharmacology</i> , 2020, 11, 551.	1.6	41
10	Get Real: Integration of Real-World Data to Improve Patient Care. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 722-725.	2.3	6
11	Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 434-437.	1.3	14
12	Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin. <i>Clinical Pharmacokinetics</i> , 2019, 58, 815-826.	1.6	25
13	Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 97-104.	0.6	34
14	Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 785-787.	1.3	84
15	Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Commentary. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 303-303.	1.0	4
16	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <i>Lancet Haematology</i> , 2016, 3, e526-e536.	2.2	197
17	Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model. <i>Pharmaceutical Research</i> , 2016, 33, 1133-1143.	1.7	12
18	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. <i>Clinical Pharmacokinetics</i> , 2016, 55, 711-721.	1.6	47

#	ARTICLE	IF	CITATIONS
19	Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00131.	1.1	127
20	Development of an Extended-Release Formulation of Capecitabine Making Use of In Vitroâ€“In Vivo Correlation Modelling. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 478-484.	1.6	6
21	Oxymorphone Active Uptake at the Bloodâ€“Brain Barrier and Population Modeling of its Pharmacokineticâ€“Pharmacodynamic Relationship. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3320-3331.	1.6	28
22	A Time-to-Event Model for Acute Rejections in Paediatric Renal Transplant Recipients Treated with Cyclosporin A. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, n/a-n/a.	1.1	14
23	Model-Based Evaluation of Similarity in Pharmacokinetics of Two Formulations of the Blood-Derived Plasma Product C1 Esterase Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 204-213.	1.0	2
24	Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses. <i>AAPS Journal</i> , 2012, 14, 601-611.	2.2	28
25	Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). <i>Investigational New Drugs</i> , 2012, 30, 1519-1530.	1.2	8
26	Modelâ€“based treatment optimization of a novel VEGFR inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 315-326.	1.1	18
27	Pharmacodynamic Biomarkers in Model-Based Drug Development in Oncology. <i>Current Clinical Pharmacology</i> , 2011, 6, 30-40.	0.2	10
28	PiraÃ±a and PCluster: A modeling environment and cluster infrastructure for NONMEM. <i>Computer Methods and Programs in Biomedicine</i> , 2011, 101, 72-79.	2.6	282
29	Evaluation of Î±2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies. <i>AAPS Journal</i> , 2011, 13, 230-239.	2.2	16
30	Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. <i>Investigational New Drugs</i> , 2011, 29, 984-995.	1.2	22
31	An Integrated Pharmacokinetic Model for the Influence of CYP3A4 Expression on the In Vivo Disposition of Lopinavir and Its Modulation by Ritonavir. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2508-2515.	1.6	16
32	â€“Floodingâ€™ of the lungs and severe dyspnea in a patient with bronchoalveolar carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 270-273.	0.5	1
33	Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. <i>Clinical Pharmacokinetics</i> , 2010, 49, 493-507.	1.6	564
34	Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. <i>Investigational New Drugs</i> , 2009, 27, 140-152.	1.2	21
35	Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2855-2860.	1.4	141
36	Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 57-63.	0.8	2